EMERGENT BIOSOLUTIONS INC (FORMERLY BIOPORT CORPORATION)

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

1999–2016

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2016	—	1	1
2015	—	4	1
2014	—	4	1
2013	—	4	1
2012	—	4	1
2011	—	4	1
2010	—	4	1
2009	—	4	1
2008	—	4	1
2007	—	3	1
2006	—	1	1
2005	—	1	1
2004	—	1	1
2003	—	2	1
2002	—	1	1
2001	—	1	1
2000	—	2	1
1999	—	1	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
DALRYMPLE & ASSOCIATES, LLC	—	46

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
Health & Human Services, Dept of (HHS)	44
Defense, Dept of (DOD)	43
HOUSE OF REPRESENTATIVES	43
SENATE	43
Homeland Security, Dept of (DHS)	41
Centers For Disease Control & Prevention (CDC)	38
White House Office	38
Food & Drug Administration (FDA)	34
Natl Institutes of Health (NIH)	32
Defense Threat Reduction Agency (DTRA)	31
Army, Dept of (Other)	27
Ballistic Missile Defense Organization	25
State, Dept of (DOS)	6
Defense Logistics Agency	5
Joint Chiefs of Staff	5
Defense Advanced Research Projects Agency (DARPA)	4
Air Force, Dept of	2
Health Resources & Services Administration (HRSA)	1
Natl Institute on Alcohol Abuse & Alcoholism (NIAA)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Defense	Defense	46
Homeland Security	Homeland Security	37
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	35
Health Issues	Health Issues	12
Pharmacy	Pharmacy	1
Budget/Appropriations	Budget/Appropriations	1

Bills Explicitly Cited (23)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1300114th Congress

First Responder Anthrax Preparedness Act

2016 · first_quarter · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Increased appropriations for CDC strategic national stockpile; increased appropriations for BARDA CBRN MCM advanced development; inceased appropriations for Project BioShield SRF; HR1300/S.1915-making anthrax vaccine available to 1st responders from the SNS prior to shelf live expiration for voluntary vaccination programs & HR 3299 for FDA priority review vouchers for developers of FDA approved MCMs against WMD CBRN threats.Contracting with CDC, HHS ASPR, BARDA and NIH for FDA licensed anthrax vaccine, botulinum antitoxin, AIGIV, BIGIV, VIGIV, third generation anthrax vaccine advanced development, RSDL for CHEMPACK,

Client expense: — · Firm income: $31,000

Matched citations: HR1300

H.R. 3299114th Congress

Strengthening Public Health Emergency Response Act of 2016

2016 · first_quarter · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Increased appropriations for CDC strategic national stockpile; increased appropriations for BARDA CBRN MCM advanced development; inceased appropriations for Project BioShield SRF; HR1300/S.1915-making anthrax vaccine available to 1st responders from the SNS prior to shelf live expiration for voluntary vaccination programs & HR 3299 for FDA priority review vouchers for developers of FDA approved MCMs against WMD CBRN threats.Contracting with CDC, HHS ASPR, BARDA and NIH for FDA licensed anthrax vaccine, botulinum antitoxin, AIGIV, BIGIV, VIGIV, third generation anthrax vaccine advanced development, RSDL for CHEMPACK,

Client expense: — · Firm income: $31,000

Matched citations: HR 3299

S. 1915114th Congress

First Responder Anthrax Preparedness Act

2016 · first_quarter · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Increased appropriations for CDC strategic national stockpile; increased appropriations for BARDA CBRN MCM advanced development; inceased appropriations for Project BioShield SRF; HR1300/S.1915-making anthrax vaccine available to 1st responders from the SNS prior to shelf live expiration for voluntary vaccination programs & HR 3299 for FDA priority review vouchers for developers of FDA approved MCMs against WMD CBRN threats.Contracting with CDC, HHS ASPR, BARDA and NIH for FDA licensed anthrax vaccine, botulinum antitoxin, AIGIV, BIGIV, VIGIV, third generation anthrax vaccine advanced development, RSDL for CHEMPACK,

Client expense: — · Firm income: $31,000

Matched citations: S.1915

H.R. 1300114th Congress

First Responder Anthrax Preparedness Act

2015 · fourth_quarter · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Increased appropriations for CDC strategic national stockpile; increased appropriations for BARDA CBRN MCM advanced development; inceased appropriations for Project BioShield SRF; HR1300/S.1915-making anthrax vaccine available to 1st responders from the SNS prior to shelf live expiration for voluntary vaccination programs & HR 3299 for FDA priority review vouchers for developers of FDA approved MCMs against WMD CBRN threats.Contracting with CDC, HHS ASPR, BARDA and NIH for FDA licensed anthrax vaccine, botulinum antitoxin, AIGIV, BIGIV, VIGIV, third generation anthrax vaccine advanced development, RSDL for CHEMPACK,

Client expense: — · Firm income: $46,000

Matched citations: HR1300

Show 19 more cited filings

H.R. 3299114th Congress

Strengthening Public Health Emergency Response Act of 2016

2015 · fourth_quarter · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Increased appropriations for CDC strategic national stockpile; increased appropriations for BARDA CBRN MCM advanced development; inceased appropriations for Project BioShield SRF; HR1300/S.1915-making anthrax vaccine available to 1st responders from the SNS prior to shelf live expiration for voluntary vaccination programs & HR 3299 for FDA priority review vouchers for developers of FDA approved MCMs against WMD CBRN threats.Contracting with CDC, HHS ASPR, BARDA and NIH for FDA licensed anthrax vaccine, botulinum antitoxin, AIGIV, BIGIV, VIGIV, third generation anthrax vaccine advanced development, RSDL for CHEMPACK,

Client expense: — · Firm income: $46,000

Matched citations: HR 3299

S. 1915114th Congress

First Responder Anthrax Preparedness Act

2015 · fourth_quarter · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Increased appropriations for CDC strategic national stockpile; increased appropriations for BARDA CBRN MCM advanced development; inceased appropriations for Project BioShield SRF; HR1300/S.1915-making anthrax vaccine available to 1st responders from the SNS prior to shelf live expiration for voluntary vaccination programs & HR 3299 for FDA priority review vouchers for developers of FDA approved MCMs against WMD CBRN threats.Contracting with CDC, HHS ASPR, BARDA and NIH for FDA licensed anthrax vaccine, botulinum antitoxin, AIGIV, BIGIV, VIGIV, third generation anthrax vaccine advanced development, RSDL for CHEMPACK,

Client expense: — · Firm income: $46,000

Matched citations: S.1915

H.R. 5533107th Congress

Department of Veterans Affairs Claims Backlog Reduction Act of 2002

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

BioShield, Biodefense vaccine biological R&D, procurement for Strategic National Stockpile, & product liability related oversight, authorizing, & appropriations legislation; DHHS & CDC procurement of anthrax vaccines; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1880, H.R 2863

Client expense: — · Firm income: $100,000

Matched citations: H.R. 5533

H.R. 5533107th Congress

Department of Veterans Affairs Claims Backlog Reduction Act of 2002

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Project BioShield and bioterrorism preparedness authorization and appropriatons legislation and related oversight issues; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1889, H.R. 2863

Client expense: — · Firm income: $100,000

Matched citations: H.R. 5533

H.R. 5533107th Congress

Department of Veterans Affairs Claims Backlog Reduction Act of 2002

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Defense authorization and appropriations legislation, MILVAX Program, Biodefense and biological product acquisition and R&D issues; S. 3678, S. 2564, H.R. 5533, S. 3708, H.R 5647

Client expense: — · Firm income: $100,000

Matched citations: H.R. 5533

H.R. 5647107th Congress

To authorize the duration of the base contract of the Navy-Marine Corps Intranet contract to be more than five years but not more than seven years.

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Defense authorization and appropriations legislation, MILVAX Program, Biodefense and biological product acquisition and R&D issues; S. 3678, S. 2564, H.R. 5533, S. 3708, H.R 5647

Client expense: — · Firm income: $100,000

Matched citations: H.R 5647

H.R. 5647107th Congress

To authorize the duration of the base contract of the Navy-Marine Corps Intranet contract to be more than five years but not more than seven years.

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Project BioShield and bioterrorism preparedness authorization and appropriatons legislation and related oversight issues; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1889, H.R. 2863

Client expense: — · Firm income: $100,000

Matched citations: H.R. 5647

H.R. 5647107th Congress

To authorize the duration of the base contract of the Navy-Marine Corps Intranet contract to be more than five years but not more than seven years.

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

BioShield, Biodefense vaccine biological R&D, procurement for Strategic National Stockpile, & product liability related oversight, authorizing, & appropriations legislation; DHHS & CDC procurement of anthrax vaccines; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1880, H.R 2863

Client expense: — · Firm income: $100,000

Matched citations: H.R. 5647

S. 1880109th Congress

National Biodefense and Pandemic Preparedness Act of 2005

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

BioShield, Biodefense vaccine biological R&D, procurement for Strategic National Stockpile, & product liability related oversight, authorizing, & appropriations legislation; DHHS & CDC procurement of anthrax vaccines; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1880, H.R 2863

Client expense: — · Firm income: $100,000

Matched citations: S. 1880

S. 1889109th Congress

Comprehensive Entitlement Reform Commission Act of 2005

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Project BioShield and bioterrorism preparedness authorization and appropriatons legislation and related oversight issues; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1889, H.R. 2863

Client expense: — · Firm income: $100,000

Matched citations: S. 1889

S. 2564109th Congress

Biodefense and Pandemic Vaccine and Drug Development Act of 2006

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Defense authorization and appropriations legislation, MILVAX Program, Biodefense and biological product acquisition and R&D issues; S. 3678, S. 2564, H.R. 5533, S. 3708, H.R 5647

Client expense: — · Firm income: $100,000

Matched citations: S. 2564

S. 2564109th Congress

Biodefense and Pandemic Vaccine and Drug Development Act of 2006

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

BioShield, Biodefense vaccine biological R&D, procurement for Strategic National Stockpile, & product liability related oversight, authorizing, & appropriations legislation; DHHS & CDC procurement of anthrax vaccines; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1880, H.R 2863

Client expense: — · Firm income: $100,000

Matched citations: S. 2564

S. 2564109th Congress

Biodefense and Pandemic Vaccine and Drug Development Act of 2006

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Project BioShield and bioterrorism preparedness authorization and appropriatons legislation and related oversight issues; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1889, H.R. 2863

Client expense: — · Firm income: $100,000

Matched citations: S. 2564

S. 3678109th Congress

Pandemic and All-Hazards Preparedness Act

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Defense authorization and appropriations legislation, MILVAX Program, Biodefense and biological product acquisition and R&D issues; S. 3678, S. 2564, H.R. 5533, S. 3708, H.R 5647

Client expense: — · Firm income: $100,000

Matched citations: S. 3678

S. 3678109th Congress

Pandemic and All-Hazards Preparedness Act

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Project BioShield and bioterrorism preparedness authorization and appropriatons legislation and related oversight issues; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1889, H.R. 2863

Client expense: — · Firm income: $100,000

Matched citations: S. 3678

S. 3678109th Congress

Pandemic and All-Hazards Preparedness Act

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

BioShield, Biodefense vaccine biological R&D, procurement for Strategic National Stockpile, & product liability related oversight, authorizing, & appropriations legislation; DHHS & CDC procurement of anthrax vaccines; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1880, H.R 2863

Client expense: — · Firm income: $100,000

Matched citations: S. 3678

S. 3708109th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

BioShield, Biodefense vaccine biological R&D, procurement for Strategic National Stockpile, & product liability related oversight, authorizing, & appropriations legislation; DHHS & CDC procurement of anthrax vaccines; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1880, H.R 2863

Client expense: — · Firm income: $100,000

Matched citations: S. 3708

S. 3708109th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Project BioShield and bioterrorism preparedness authorization and appropriatons legislation and related oversight issues; S. 2564, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1889, H.R. 2863

Client expense: — · Firm income: $100,000

Matched citations: S. 3708

S. 3708109th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007

2006 · year_end · Firm: DALRYMPLE & ASSOCIATES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Defense authorization and appropriations legislation, MILVAX Program, Biodefense and biological product acquisition and R&D issues; S. 3678, S. 2564, H.R. 5533, S. 3708, H.R 5647

Client expense: — · Firm income: $100,000

Matched citations: S. 3708

Source: Senate LDA

EMERGENT BIOSOLUTIONS INC (FORMERLY BIOPORT CORPORATION) — Lobbying Disclosure | Poliscope